Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent effect through AMPK signaling

被引:28
作者
Abdelkader, Noha F. [1 ]
Elbaset, Marawan A. [2 ]
Moustafa, Passant E. [2 ]
Ibrahim, Sherehan M. [1 ]
机构
[1] Cairo Univ, Dept Pharmacol & Toxicol, Fac Pharm, Kasr El Aini St, Cairo 11562, Egypt
[2] Natl Res Ctr, Med Res & Clin Studies Inst, Pharmacol, Giza, Egypt
关键词
Empagliflozin; Dorsomorphin; Diabetic peripheral neuropathy; AMPK; p38; MAPK; mTOR; ACTIVATED PROTEIN-KINASE; SPINAL NERVE LIGATION; OXIDATIVE STRESS; MECHANICAL ALLODYNIA; RAT MODEL; METFORMIN; PAIN; INHIBITION; AUTOPHAGY; NEURONS;
D O I
10.1007/s12272-022-01391-5
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Diabetic peripheral neuropathy (DPN) represents a severe microvascular condition that dramatically affects diabetic patients despite adequate glycemic control, resulting in high morbidity. Thus, recently, anti-diabetic drugs that possess glucose-independent mechanisms attracted attention. This work aims to explore the potentiality of the selective sodium-glucose cotransporter-2 inhibitor, empagliflozin (EMPA), to ameliorate streptozotocin-induced DPN in rats with insight into its precise signaling mechanism. Rats were allocated into four groups, where control animals received vehicle daily for 2 weeks. In the remaining groups, DPN was elicited by single intraperitoneal injections of freshly prepared streptozotocin and nicotinamide (52.5 and 50 mg/kg, respectively). Then EMPA (3 mg/kg/p.o.) was given to two groups either alone or accompanied with the AMPK inhibitor dorsomorphin (0.2 mg/kg/i.p.). Despite the non-significant anti-hyperglycemic effect, EMPA improved sciatic nerve histopathological alterations, scoring, myelination, nerve fibers' count, and nerve conduction velocity. Moreover, EMPA alleviated responses to different nociceptive stimuli along with improved motor coordination. EMPA modulated ATP/AMP ratio, upregulated p-AMPK while reducing p-p38 MAPK expression, p-ERK1/2 and consequently p-NF-kappa B p65 as well as its downstream mediators (TNF-alpha and IL-1 beta), besides enhancing SOD activity and lowering MDA content. Moreover, EMPA downregulated mTOR and stimulated ULK1 as well as beclin-1. Likewise, EMPA reduced miR-21 that enhanced RECK, reducing MMP-2 and -9 contents. EMPA's beneficial effects were almost abolished by dorsomorphin administration. In conclusion, EMPA displayed a protective effect against DPN independently from its anti-hyperglycemic effect, probably via modulating the AMPK pathway to modulate oxidative and inflammatory burden, extracellular matrix remodeling, and autophagy.
引用
收藏
页码:475 / 493
页数:19
相关论文
共 88 条
[1]   Blunting p38 MAPKa and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation in mice intoxicated with carbon tetrachloride [J].
Abdelhamid, Amir Mohamed ;
Youssef, Mahmoud E. ;
Abd El-Fattah, Eslam E. ;
Gobba, Naglaa A. ;
Gaafar, Ahmed Gaafar Ahmed ;
Girgis, Samuel ;
Shata, Ahmed ;
Hafez, Abdel-Moneim ;
El-Ahwany, Eman ;
Amin, Noha A. ;
Shahien, Mohamed Awad ;
Abd-Eldayem, Marwa A. ;
Abou-Elrous, Magdy ;
Saber, Sameh .
LIFE SCIENCES, 2021, 286
[2]   Inosine mitigated diabetic peripheral neuropathy via modulating GLO1/AGEs/RAGE/NF-κB/Nrf2 and TGF-β/PKC/TRPV1 signaling pathways [J].
Abdelkader, Noha F. ;
Ibrahim, Sherehan M. ;
Moustafa, Passant E. ;
Elbaset, Marawan A. .
BIOMEDICINE & PHARMACOTHERAPY, 2022, 145
[3]   Neuroprotective effect of nebivolol against cisplatin-associated depressive-like behavior in rats [J].
Abdelkader, Noha F. ;
Saad, Muhammed A. ;
Abdelsalam, Rania M. .
JOURNAL OF NEUROCHEMISTRY, 2017, 141 (03) :449-460
[4]   Inhibition of p38 MAP kinase corrects biochemical and neurological deficits in experimental diabetic neuropathy [J].
Agthong, S ;
Tomlinson, DR .
CELL SIGNALING, TRANSCRIPTION, AND TRANSLATION AS THERAPEUTIC TARGETS, 2002, 973 :359-362
[5]   Detection of cold pain, cold allodynia and cold hyperalgesia in freely behaving rats [J].
Allchorne, Andrew J. ;
Broom, Daniel C. ;
Woolf, Clifford J. .
MOLECULAR PAIN, 2005, 1
[6]  
Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc12-s064, 10.2337/dc10-S011, 10.2337/dc13-S067, 10.2337/dc11-S011, 10.2337/dc12-s011, 10.2337/dc11-S062, 10.2337/dc14-S081, 10.2337/dc10-S062, 10.2337/dc13-S011]
[7]   Effect of Xylopic Acid on Paclitaxel-induced Neuropathic pain in rats [J].
Ameyaw, E. O. ;
Boampong, J. N. ;
Kukuia, K. E. ;
Amoateng, P. ;
Obese, E. ;
Osei-Sarpong, C. ;
Woode, E. .
JOURNAL OF MEDICAL AND BIOMEDICAL SCIENCE, 2013, 2 (04) :6-12
[8]   Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury [J].
Anand, Praveen ;
Shenoy, Ravikiran ;
Palmer, Joanne E. ;
Baines, Amanda J. ;
Lai, Robert Y. K. ;
Robertson, Jonathan ;
Bird, Nick ;
Ostenfeld, Thor ;
Chizh, Boris A. .
EUROPEAN JOURNAL OF PAIN, 2011, 15 (10) :1040-1048
[9]  
[Anonymous], 2012, JAMA-J AM MED ASSOC, DOI DOI 10.1001/JAMA.308.16.1694-A
[10]  
Asiedu MN, 2016, EXPERIENTIA SUPPL, V107, P257, DOI 10.1007/978-3-319-43589-3_11